Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Vincent, Emma E ^a   Elder, Douglas J E ^a   Curwen, Jon ^b   Kilgour, Elaine ^b   Hers, Ingeborg ^a   Tavaré, Jeremy M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AZ 12253801; INSULIN; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHAIR3; MONOCLONAL ANTIBODY IR47 9; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; COMPETITIVE INHIBITION; CONTROLLED STUDY; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; ISOXAZOLES; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84879491317     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066963     Document Type: Article

References (64)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181.
3. Cataldo VD, Gibbons DL, Perez-Soler R, Quintas-Cardama A, (2011) Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 364: 947-955.
4. Neal JW, Sequist LV, (2010) Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 11: 36-44.
5. Pollak M, (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
6. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512.
7. Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K, (1990) Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 270: 383-390.
8. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, et al. (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19: 3278-3288.
9. Brown J, Delaine C, Zaccheo OJ, Siebold C, Gilbert RJ, et al. (2008) Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 27: 265-276.
10. Dziadziuszko R, Camidge DR, Hirsch FR, (2008) The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 3: 815-818.
11. Werner H, Bruchim I, (2009) The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 115: 58-71.
12. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, et al. (2010) The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs 19: 631-639.
13. Massoner P, Ladurner-Rennau M, Eder IE, Klocker H, (2010) Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 103: 1479-1484.
14. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, et al. (2006) IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 13: 593-605.
15. Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E, et al. (2003) Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 64: 341-345.
16. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, et al. (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169: 714-717.
17. Werner H, LeRoith D, (1996) The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68: 183-223.
18. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, et al. (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62: 2942-2950.
19. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, et al. (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246.
20. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, et al. (1999) Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 30: 1128-1133.
21. Kornprat P, Rehak P, Ruschoff J, Langner C, (2006) Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours. J Clin Pathol 59: 202-206.
22. Gualberto A, Pollak M, (2009) Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 10: 923-936.
23. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, et al. (1992) Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 52: 3924-3930.
24. Nakanishi Y, Mulshine JL, Kasprzyk PG, Natale RB, Maneckjee R, et al. (1988) Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82: 354-359.
25. Osborne CK, Bolan G, Monaco ME, Lippman ME, (1976) Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A 73: 4536-4540.
26. Pillemer G, Lugasi-Evgi H, Scharovsky G, Naor D, (1992) Insulin dependence of murine lymphoid T-cell leukemia. Int J Cancer 50: 80-85.
27. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, et al. (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736-3740.
28. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, et al. (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277: 39684-39695.
29. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, et al. (2010) Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 29: 2517-2527.
30. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, et al. (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-2452.
31. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D (2010) Inaugural Article: Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A.
32. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, et al. (2010) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21: 562-567.
33. Kaiser U, Schardt C, Brandscheidt D, Wollmer E, Havemann K, (1993) Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J Cancer Res Clin Oncol 119: 665-668.
34. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, et al. (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20: 842-849.
35. Chang YS, Wang L, Liu D, Mao L, Hong WK, et al. (2002) Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 3669-3675.
36. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, et al. (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156.
37. Karey KP, Sirbasku DA, (1988) Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res 48: 4083-4092.
38. Favoni RE, de Cupis A, Ravera F, Cantoni C, Pirani P, et al. (1994) Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 56: 858-866.
39. Zhu CQ, Popova SN, Brown ER, Barsyte-Lovejoy D, Navab R, et al. (2007) Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc Natl Acad Sci U S A 104: 11754-11759.
40. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, et al. (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27: 2516-2522.
41. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, et al. (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatinversus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: (suppl; abstr 7500).
42. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, et al. (2010) Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5: e14124.
43. Dalby AR, Emam I, Franke R, (2012) Analysis of gene expression data from non-small cell lung carcinoma cell lines reveals distinct sub-classes from those identified at the phenotype level. PLoS One 7: e50253.
44. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, et al. (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4: 521-528.
45. Vincent EE, Elder DJ, Phillips L, Heesom KJ, Pawade J, et al. (2011) Overexpression of the TXNDC5 Protein in Non-small Cell Lung Carcinoma. Anticancer Res 31: 1577-1582.
46. Kull FC Jr, Jacobs S, Su YF, Svoboda ME, Van Wyk JJ, et al. (1983) Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 258: 6561-6566.
47. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, et al. (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63: 627-635.
48. Gong Y, Yao E, Shen R, Goel A, Arcila M, et al. (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 4: e7273.
49. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, et al. (1996) Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271: 11477-11483.
50. Carboni JM, Wittman M, Yang Z, Lee F, Greer A, et al. (2009) BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 8: 3341-3349.
51. Dent P, Han SI, Mitchell C, Studer E, Yacoub A, et al. (2005) Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem Pharmacol 70: 1685-1696.
52. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, et al. (2004) The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 3: 527-535.
53. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, et al. (2010) Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 9: 2593-2604.
54. Vincent EE, Elder DJ, Thomas EC, Phillips L, Morgan C, et al. (2011) Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer.
55. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, et al. (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059.
56. David O, Jett J, LeBeau H, Dy G, Hughes J, et al. (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871.
57. Pal SK, Reckamp K, Yu H, Figlin RA, (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355-1366.
58. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW, (2008) Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 60: 166-174.
59. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, et al. (2004) Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64: 6252-6258.
60. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, et al. (2006) Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 5: 114-120.
61. Prince SN, Foulstone EJ, Zaccheo OJ, Williams C, Hassan AB, (2007) Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor. Mol Cancer Ther 6: 607-617.
62. Basu B, Olmos D, de Bono JS, (2011) Targeting IGF-1R: throwing out the baby with the bathwater? Br J Cancer 104: 1-3.
63. Gualberto A, Hixon ML, Karp DD, Li D, Green S, et al. (2011) Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74.
64. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, et al. (2010) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16: 4654-4665.